{"ok":true,"nota":{"id":"4782472a3e78d3f0","slug":"logran-fabricar-en-levaduras-una-pildora-oral-de-un-medicamento-inyect-478247","titulo":"Logran fabricar en levaduras una píldora oral de un medicamento inyectable para la diabetes y la obesidad","resumen":"Investigadores modificaron genéticamente una levadura común para que produzca un péptido similar a los fármacos GLP-1/GIP, pensado para tomarse por boca en vez de inyectarse. Obtuvieron unos 4 mg por gramo de biomasa seca y realizaron una primera evaluación clínica preliminar.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Kwon, K.-C., Gaidarenko, O., Chang, N., Henderson, C.","url":"https://www.medrxiv.org/content/10.64898/2026.10.22.26365662v1?rss=1","imagen":"/hoy/portada/4782472a3e78d3f0","tema":"ciencia","subtemas":["farmacologia","biotecnologia","diabetes","levaduras","medicamentos orales"],"entidades":["Saccharomyces cerevisiae","medRxiv"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-24T00:00:00.000Z","indexTs":"2026-10-24T16:02:27.654Z","hash":"a6e0e8ec1e704c1a1a9aaf50c27788017a7a993cbbd1564d240ea2cc3d7d851c","tsa":{"time":"Oct 24 16:02:47 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Hoy estos medicamentos requieren inyecciones porque el estómago y el intestino destruyen las proteínas antes de que lleguen a la sangre. Si este método llega a funcionar en personas, podría abaratar y simplificar el tratamiento para millones de pacientes, incluidos los argentinos que hoy no toleran las agujas. Todavía es una fase temprana, y pasar del laboratorio a una pastilla de farmacia suele llevar años.","quienFirma":"Universidad no especificada en el resumen disponible","confianza":"preprint","consulta":null},"sello":{"hash":"a6e0e8ec1e704c1a1a9aaf50c27788017a7a993cbbd1564d240ea2cc3d7d851c","sello":"6484c5316a9d1e90d672ff8db49d52f2e7d02049eab92120d99413a350bfa260","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6580890,"aleatorio":"10b843f815aa592890ab5708bbe3e30aa649ae4903f4b04ddbaea43ecdff5368","tiempo":"2026-10-24T16:02:00.000Z"},"nist":{"cadena":2,"pulso":1997638,"salida":"DC8390B2FC8E41804FBC87410481560B6FD9A3106ED549AAA1ED207C199FF576B4E5003E4E7503F6C74985AB90AFA7E81F35A2A0C13763958FE82A55C83DB3FA","tiempo":"2026-10-24T16:01:00.000Z"},"noAntes":"2026-10-24T16:02:00.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 24 16:02:47 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"A Yeast-Based Platform for Oral Delivery of a Dual GLP-1/GIP Receptor Agonist: Engineering and Preliminary Clinical Evaluation","descripcion":"Oral delivery of peptides and other biologics is limited by enzymatic degradation and poor intestinal permeability. We developed a Saccharomyces cerevisiae-based platform expressing pro-DALAP, a fusion precursor of a dual GLP-1/GIP receptor agonist. The construct incorporates maltose-binding protein, a GM1-binding peptide, a cell-penetrating peptide, furin cleavage sites, and an albumin-binding domain, designed to support peptide stability, epithelial uptake, proteolytic activation, and prolonged systemic exposure. CRISPR/Cas12a-mediated integration of three expression cassettes into a protease-deficient yeast strain yielded 4.05 +/- 0.31 mg pro-DALAP/g dry biomass, compared with 1.27 +/- 0.","pubDate":"2026-10-24","url":"https://www.medrxiv.org/content/10.64898/2026.10.22.26365662v1?rss=1"},"indexado":"2026-10-24T16:02:27.654Z"}}